What is the robustness of randomized controlled trials supporting rhinosinusitis guidelines?
The RCTs used to support the ICAR-RS have an overall low robustness and future rhinosinusitis trials should report FI measures to provide improved context of their results.
Authors
- Omar G. Ahmed (ORCID: https://orcid.org/0000-0002-0920-2325)
- Murugappan Ramanathan (ORCID: https://orcid.org/0000-0002-7612-9586)
- Edward D. McCoul (ORCID: https://orcid.org/0000-0003-1812-2105)
- Wenqi Jin
- Yuki Yoshiyasu (ORCID: https://orcid.org/0000-0002-4127-1048)
- Najm S. Khan (ORCID: https://orcid.org/0000-0003-2701-4798)
- Masayoshi Takashima (ORCID: https://orcid.org/0000-0001-9790-3529)
- Aatin K. Dhanda (ORCID: https://orcid.org/0000-0002-8926-7662)
- Wenbo Wu (ORCID: https://orcid.org/0000-0002-7642-9773)
- Richard Liu (ORCID: https://orcid.org/0000-0002-0949-9229)
Institutions
- Houston Methodist (US)
- Johns Hopkins University (US)
- Baylor College of Medicine (US)
- Ochsner Medical Center (US)
- Johns Hopkins Medicine (US)
- Johnson University (US)
- Methodist Hospital (US)
- The University of Texas Medical Branch at Galveston (US)
- New York University (US)
Publication Details
- Journal
- American Journal of Otolaryngology
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1016/j.amjoto.2024.104575
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00